Article and Video CATEGORIES
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University
Topics include:
- Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'
- Updates in DLBCL
- Treatment Basics of Bone Marrow Transplant
- Frontline Therapies in Myelofibrosis
- Panel Discussions and a Question-and-Answer session
Image
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO.
To watch the complete playlist, click here.
Image
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Forum Discussions
Hi Stan,
It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving. I know it meant a...
Hi Stan! It is good to hear from you -- I am so very happy you are doing well. I agree with Janine that family and friends - our chosen family...
Recent Comments
Hey Bluebird,
I understand…
I understand…
By JanineT GRACE … on
Thank you, Janine
By Bluebird on